Is Neurocrine Biosciences Inc (NBIX) a risky stock?
As of July 23, 2026, Clavix grades Neurocrine Biosciences Inc (NBIX) A for risk, a composite score of 88 out of 100 on an A+ to F scale, which puts NBIX in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 23, 2026. Clavix regrades every trading day.
The five risk dimensions behind NBIX's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how NBIX scores on each, as of July 23, 2026.
What's moving NBIX's risk right now
Company-specific signals Clavix flags behind NBIX's current grade, drawn from recent news and filings as of July 23, 2026.
SEB Asset Management started a new 79,577-share position in NBIX during Q1, while Allspring Global Investments reduced its holdings by 2.1%. The opposite moves roughly cancel out, leaving institutional news signal little changed.
Recent NBIX news
The latest headlines Clavix ingested for Neurocrine Biosciences Inc, newest first. These feed the news-sentiment dimension of NBIX's grade.
-
Neurocrine Biosciences (NBIX) has appointed Samir Siddhanti as Chief Business Officer, with him also joining the company's executive Management Committee.
What a A grade means
On the Clavix A+ to F scale, NBIX's composite of 88 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell NBIX or any security. Grades are risk indicators, not predictions of return. Data may be delayed.